Detection of cancer by elevated levels of BCL-2

Details Detection of cancer by elevated levels of BCL-2 Detection of cancer by elevated levels of BCL-2

2007-02-09

2011-10-11

Yu, Misook (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

C435S007230, C435S007100

Reexamination Certificate

active

08034549

ABSTRACT:
The present invention relates to a method for the diagnosis, prognosis, and monitoring of cancer, such as early or late stage ovarian cancer, in a subject by detecting Bcl-2 in a biological sample from the subject, preferably a urine or blood sample. Bcl-2 may be measured using an agent that detects or binds to Bcl-2 protein or an agent that detects or binds to encoding nucleic acids, such as antibodies specifically reactive with Bcl-2 protein or a portion thereof. The invention further relates to kits for carrying out the methods of the invention. The invention further relates to a device for the rapid detection of Bcl-2 in a bodily fluid and methods for rapidly measuring Bcl-2 in a bodily fluid.

REFERENCES:
patent: 5015568 (1991-05-01), Tsujimoto et al.
patent: 5459251 (1995-10-01), Tsujimoto et al.
patent: 5506344 (1996-04-01), Tsujimoto et al.
patent: 5523393 (1996-06-01), Tsujimoto et al.
patent: 5595869 (1997-01-01), Tsujimoto et al.
patent: 5641866 (1997-06-01), Reed et al.
patent: 6130201 (2000-10-01), Croce et al.
patent: 6207452 (2001-03-01), Govindaswamy
patent: 2002/0106731 (2002-08-01), Ruben et al.
patent: 2004/0137538 (2004-07-01), Bradford
patent: 10-2003-0092378 (2003-12-01), None
patent: 2262939 (2005-10-01), None
patent: WO-01-11361 (2001-02-01), None
patent: WO-02/090931 (2002-11-01), None
patent: WO-03-078662 (2003-09-01), None
Kibel, AS et al, 2000, J urol, 164(1): 192-6.
Dong et al, 2000, Cancer Research, 60: 3880-3883.
Zhau, HE, 1994, J Cell Biochem, Suppl 19: 208-216.
Ren, C et al, 1998, Cancer Res, 58(6): 1285-90.
Gingrich, JR et al, 1996, Cancer res, 56(18): 4096-4102.
Russo, V et al, 1995, Int J Cancer, 64: 216-221.
Li et al, 2005, Arch Gynecol Obstet, 272: 48-52.
Tas et al, Jun. 2006, Medical Oncol, 23(2): 213-217.
Ohkaru et al, 1995, J Immunol method, 178: 99-111.
Ackermann, E. J. et al., “The Role of Antiapoptotic Bcl-2 Family Members in Endothelial Apoptosis Elucidated with Antisense Oligonucleotides”J. Biol. Chem., 1999, 274:11245-11252.
Farrow, S.N. and Brown, R. “New members of the Bcl-2 family and their protein partners”Curr. Opin. Gen. Dev., 1996 6:45-49.
Hanaoka, T. et al., “Immunohistochemical demonstration of apoptosis-regulated proteins, Bcl-2 and Bax, in resected non-small-cell lung cancers”Intl. J. Clin. Oncol., 2002, 7:152-158.
Khalifeh, I. et al., “Expression of Cox-2, CD34, Bcl-2, and p53 and Survival in Patients with Primary Peritoneal Serous Carcinoma and Primary Ovarian Serous Carcinoma”Int. J. Gynecol. Pathol., 2004, 23:162-169.
Lickliter, J.D et al. “HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death”Leukemia, 2003, 17:2074-2080.
O'Neill, C.J. et al. “An Immunohistochemical Comparison Between Low-Grade and High-Grade Ovarian Serous Carcinomas”Am, J. Surg. Pathol., 2005 29:1034-1041.
Sharma, H. et al. “Combined evaluation of expression of telomerase, surviving, and anti-apoptotic Bcl-2 family members in relation to loss of differentiation and apoptosis in human head and neck cancers”Head Neck, 2004, 26:733-740.
Thomenius, M.J. and Distelhorst, C.W. “Bcl-2 on the endoplasmic reticulum: protecting the mitochondria from a distance”J. Cell Sci., 2003, 116:4493-44990.
Trisciuoglio, D. et al. “Bcl-2 Overexpression in Melanoma Cells Increases Tumor Progression-Associated Properties and in Vivo Tumor Growth”J. Cell Physiol., 2005, 205:414-421.
Eissa, S. et al. “Quantitation of bcl-2 protein in bladder cancer tissue by enzyme immunoassay: comparison with Western blot and immunohistochemistry”Clinical Chemistry, 1998, 44(7): 1423-1429.
Hussain, S. A. et al. “BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder”Oncology Reports, 2003, 10: 571-576.
Friedrich, M. G. et al. “Detection of Methylated Apoptosis-Associated Genes in Urine Sediments of Bladder Cancer Patients”Clinical Cancer Research, 2004, 10: 7457-7465.
Ziaee, S. A. et al. “Diagnosis of Bladder Cancer by Urine Survivin, an Inhibitor of Apoptosis”Urological Oncology, 2006, 3(3): 150-153.
Abramenko, I.V. and Filchenkov, A.A. “Evaluation of apopotosis and diagnosis of cancer, prognosis and improvement of therapy”Voprosy Onkologii(St. Petersburg), 2003, 49(1):21-30, abstract.
Cao, Y. et al. “Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients”Int. J Mol Med, 2000, 5:547-551.
Smith, S.D. et al. “Urine Detection of Survivin and Diagnosis of Bladder Cancer”JAMA, 2001, 285:324-328.
Johnson, N. C. et al. “Detection of Bcl-2 and Survivin in Urine and Imidazome-treated Plasma for Ovarian Disease” presented at the University of South Florida Health Sciences Research Day, Feb. 26, 2004, pp. 1-8.
Johnson, N. C. et al. “Screening plasma and urine from women with ovarian disease for Bcl-2, survivin and telomerase”Proc Amer Assoc Cancer Res, 2004, vol. 45, Abstract #1339.
Kruk, P.A. “Detection of ovarian cancer by elevated urinary levels of Bcl-2” 97thAnnual Meeting for the American Association for Cancer Research, Washington, DC, Apr. 1-5, 2006.
Kruk, P.A. “Analysis of Biomarkers in Ovarian Cancer” Biomedical Engineering Seminar Series, University of South Florida, Tampa, FL, Feb. 17, 2006.
Kruk, P.A. et al. “Detection of Ovarian Cancer by Elevated Urinary Levels of Bcl-2” 6thBiennial Ovarian Cancer Research Symposium, Seattle, WA, Sep. 8, 2006.
Kruk, P.A. et al. “Detection of Ovarian Cancer by Elevated Urinary Levels of Bcl-2”Proc Amer Assoc Cancer Res, 2006, vol. 47, Abstract #2418.
Tools for the Study of Apoptosis, pp. 1-25, Chemicon International, Inc.
Bcl-2 Sandwich ELISA KIT, pp. 1-10, Chemicon International, Inc.
Bcl 2 (B Cell Leukemia 2) BioAssay™ ELISA kit, pp. 1-2, retrieved: Jan. 23, 2007 from.
Bcl-2 Antibody, pp. 1-2, 2005, Cell Signaling Technology, Inc.
Bcl-2 Antibody (Human Specific), pp. 1-3, 2005, Cell Signaling Technology, Inc.
Product Information and Manual, human Bcl-2 ELISA BMS244/3 Enzyme-linked immunosorbent assay for quantitative detection of human Bcl-2, pp. 2-32, Jul. 28, 2005, Bender MedSystems GmbH, Campus Vienna Biocenter 2, Vienna, Austria, Europe.
Tas, F. et al., “The Value of Serum bcl-2 Levels in Advanced Epithelial Ovarian Cancer.”Medical Oncology, 2006, 23: 213-217.
Giannoulis, K. et al. (2004). Serum levels of bcl-2 in patients with colorectal cancer.Techniques in Coloproctology, 8(Supplement 1): S56-S58.
Office Action dated Feb. 22, 2011 in Russian Application No. 2008136193, filed Feb. 9, 2007.
Henriken, R. et al. (1995). Expression and prognostic significance of Bcl-2 in ovarian tumours.British Journal of Cancer, 72: 1324-1329.
Herod, J. J. O. et al. (1996). The Prognostic Significance of BcI-2 and p53 Expression in Ovarian Carcinoma.Cancer Research, 56: 2178-2184.
English translation of Office Action dated Jul. 5, 2011 in Japanese Application No. 2008-554404, filed Feb. 9, 2007.

Affiliated with

Also associated with

Rating

Detection of cancer by elevated levels of BCL-2 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Detection of cancer by elevated levels of BCL-2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detection of cancer by elevated levels of BCL-2 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4281964